This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-3037v1 69/9/3971    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Devaud, C. Articles by Capone, M. Search for Related Content PubMed PubMed Citation Articles by Devaud, C. Articles by Capone, M.

Antitumor Activity of T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model

¹ Université Bordeaux 2 and ² Centre National de la Recherche Scientifique UMR 5164, and ³ Laboratoire d'Immunologie et d'Immunogénétique, CHU Bordeaux, Bordeaux, France

Requests for reprints: Myriam Capone, UMR-Centre National de la Recherche Scientifique 5164, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux, France. Phone: 33-05-57-57-14-71; Fax: 33-05-57-57-14-72; E-mail: myriam.capone{at}u-bordeaux2.fr.

Key Words: human colon carcinoma • human T cells • mouse xenograft model • cytomegalovirus • chemokines

T cells recognize stress-induced autoantigens and contribute to immunity against infections and cancer. Our previous study revealed that V2-negative (^neg) T lymphocytes isolated from transplant recipients infected by cytomegalovirus (CMV) killed both CMV-infected cells and HT29 colon cancer cells in vitro. To investigate the antitumor effects of V2^neg clones in vivo, we generated hypodermal HT29 tumors in immunodeficient mice. Concomitant injections of V2^negclones, in contrast to V2⁺ cells, prevented the development of HT29 tumors. V2^neg clones expressed chemokine C-C motif receptor 3 (CCR3) and migrated in vitro in response to chemokines secreted by HT29 cells, among which were the CCR3 ligands macrophage inflammatory protein-1 and monocyte chemoattractant protein-4. More importantly, a systemic i.p. treatment with V2^neg clones delayed the growth of HT29 s.c. tumors. The effect of in vivo T-cell passive immunotherapy on tumor growth could be reverted by addition of a blocking anti-CCR3 antibody. T-cell passive immunotherapy was dependent on the cytotoxic activity of the effectors toward their targets because V2^neg clones were not able to inhibit the growth of A431 hypodermal tumors. Our findings suggest that CMV-specific V2^neg cells could target in vivo cancer cells, making them an attractive candidate for antitumor immunotherapy. [Cancer Res 2009;69(9):3971–8]